SHP 647

Drug Profile

SHP 647

Alternative Names: PF-00547659; PF-547659; SHP647

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Shire
  • Class Anti-inflammatories; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Alpha4beta7 integrin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis; Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 25 Jun 2018 Phase-III clinical trials in Crohn's disease (In adolescents, In adults, In the elderly, Treatment-experienced) in Lithuania, USA (SC) (EudraCT2017-000575-88) (NCT03559517)
  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2018 Shire initiates enrolment in the phase III CARMEN CD 306 trial for Crohn's disease (In adolescents, In adults, In the elderly, Treatment-experienced) in USA (SC) (NCT03566823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top